Daily Summary
Dr. Peter Marks, the FDA’s top vaccine official, resigned amid conflicts over vaccine misinformation propagated by Robert F. Kennedy Jr., reflecting deep tensions between scientific integrity and political influence at a time when public health is already under strain. Meanwhile, the Trump administration has ordered sweeping cuts to NIH-funded research—including clinical trials—raising serious concerns about participant safety and the future of biomedical research, even as efforts to boost replication studies stir debate over resource allocation. Separately, significant investments from tech moguls are propelling advanced longevity and anti-aging research, seeking not just to extend lifespan but also to improve quality of life despite potential economic and social challenges.
Top FDA Vaccine Official Resigns, Citing RFK Jr.'s 'Misinformation and Lies'
FDA's top vaccine official, Peter Marks, has resigned, accusing RFK Jr. of spreading misinformation about vaccine safety, a move that underscores ongoing concerns over the agency’s adherence to scientific truth.
FDA's Top Vaccine Official Peter Marks Forced to Resign Amid HHS Pressure
Peter Marks, FDA's top vaccine official, resigned under pressure from HHS after an ultimatum, citing conflicts with RFK Jr. over misinformation. His resignation is effective April 5, 2025.
Top US Vaccine Official Resigns Over RFK Jr.'s Misinformation
Peter Marks, the FDA's top vaccine official, resigned after accusing Health Secretary Robert F. Kennedy Jr. of spreading misinformation about vaccines, particularly amidst concerns over a measles outbreak and COVID-19 vaccine safety.
Longevity Science: How Modern Anti-Aging Research Helps Extend Life
Modern anti-aging advancements, supported by major investments, are paving the way for extended lifespans, while emphasizing the need for financial planning and improved quality of life.
NIH's Reckless Clinical Trial Cuts Under Trump Administration
The Trump administration ordered the NIH to cancel hundreds of research awards, including over 100 clinical trials, risking patient safety and jeopardizing scientific progress amid ethical concerns.
New Friction Arises Over Replicating Medical Research
The Trump administration's plan to boost funding for replicating medical research has sparked debate amid budget cuts. Key figures, including Robert F. Kennedy Jr. and Jay Bhattacharya, contend that replication is critical to address the reproducibility crisis in science.